One of the great opportunities that TVIX management must be licking their chops is the dermatologic uses of Kevetrin. Once Kevetrin is approved by the FDA to treat various tumors, the door is going to be open for dermatological tumors such as Squamous Cell Carcinoma, Basal Cell Carcinoma, Actinic Keratoses, and perhaps for uses we can’t even imagine. Dermatologists are very creative and will use medicine off label (unapproved uses) which is their right, to treat and cure an affliction. The opportunity represents well over a billion in revenues. If Kevetrin has very good efficacy, it could potentially replace 5-FU (A chemotherapy agent) which is used in high volume in dermatology offices. Perhaps Kevetrin will have a cosmetic application. It will be discovered by the partners that license Kevetrin. 

People need to realize that this isn’t the typical OTC-BB junk stock that needs lots of TA and analyses like the other inferior  stocks require to maintain an investor’s sanity. Kevetrin is being studied at HARVARD UNIVERSITY’s Dana FARBER Oncology Center!!!!!!!!!!! Please keep that in mind. We have a legitimate juggernaut once P53 is shown to be activated in the PK  studies . If there is efficacy, this is like discovering Tylenol because it’s going to be used for many disease indications.